Pulmonology · Pulmonary FibrosisTrial Updateclinicalmid-term

Boehringer Ingelheim Initiates Long-term Study of Nerandomilast in Pulmonary Fibrosis Patients

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Boehringer Ingelheim5 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/26/2026, 12:32:00 AM

Assessment confidence: 62% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of a long-term study for nerandomilast is significant as it may yield critical data on its efficacy and safety in treating pulmonary fibrosis. Positive results could enhance Boehringer Ingelheim's competitive positioning and market confidence in this therapy. Regulatory context from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) supports the near-term read. Assessment grounded in 7 ranked evidence items (3 high-relevance).

Strategic Assessment

Positive outcomes may strengthen Boehringer Ingelheim's portfolio in pulmonary fibrosis and enhance market confidence in nerandomilast. The strongest clinical anchor is A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in Previous Study With Nerandomilast (ClinicalTrials.gov), sub-indication match (ild); entity match (boehringer ingelheim). In ild, 2 regulatory and 2 competitive items passed relevance filtering for Boehringer Ingelheim.

Competitive Pressure

The most relevant competitive pressure comes from Study on Air Pollution's Impact on Cystic Fibrosis Severity in Hispanic Children (Humanexa Signals) — sub-indication match (ild).

Regulatory Outlook

Regulatory risk is concentrated around Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA). Sub-indication match (ild). The study's findings may influence future regulatory submissions and labeling for nerandomilast, depending on the demonstrated long-term safety and efficacy.

Key Risks

Elevated medium regulatory exposure for Boehringer Ingelheim could delay market entry or constrain labeling if agency review intensifies.
Regulatory risk from FDA (Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026) could weigh on Boehringer Ingelheim through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

Successful outcomes could lead to increased adoption of nerandomilast, potentially boosting revenue and market share in the pulmonary fibrosis segment.
Upside for Boehringer Ingelheim may improve if Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026 (FDA) delivers favorable follow-through.
Positive outcomes may strengthen Boehringer Ingelheim's portfolio in pulmonary fibrosis and enhance market confidence in nerandomilast.

What Would Change This Assessment

This becomes more urgent if Monitor results from lung function tests and overall patient health outcomes over the study duration.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Development of Antihypertensive Therapies for Use in Pediatric Patients - 07/15/2026
FDAhigh relevance
Sub-indication match (ild)
FDA document
View source
FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
Opportunities for patients and the public to be involved in the work of the MHRA
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in Previous Study With Nerandomilast
ClinicalTrials.govhigh relevance
Sub-indication match (ild); Entity match (boehringer ingelheim)
FDA document
View source
Home Air Pollution in Children With Cystic Fibrosis Study
ClinicalTrials.govmedium relevance
Sub-indication match (ild)
FDA document
View source
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Study on Air Pollution's Impact on Cystic Fibrosis Severity in Hispanic Children
Humanexa Signalsmedium relevance
Sub-indication match (ild)
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
Bristol Myers Squibbmedium relevance
Sponsor/company relevance (Bristol Myers Squibb)
FDA document
View source
UK-wide ENDO1000 Study Aims to Advance Endometriosis Diagnosis and Treatment
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Association between smoking and prognosis in idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
PubMedhigh relevance
Sub-indication match (ild)
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Boehringer Ingelheim

Commercial impact

medium

Successful outcomes could lead to increased adoption of nerandomilast, potentially boosting revenue and market share in the pulmonary fibrosis segment.

Regulatory impact

medium

The study's findings may influence future regulatory submissions and labeling for nerandomilast, depending on the demonstrated long-term safety and efficacy.

What to watch

Monitor results from lung function tests and overall patient health outcomes over the study duration.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.